The estimated Net Worth of Equity Opportunities V, Llc... is at least $9.93 Milión dollars as of 4 December 2020. Equity Llc owns over 4,398,602 units of Regulus Therapeutics Inc stock worth over $9,934,626 and over the last 6 years Equity sold RGLS stock worth over $0.
Equity has made over 2 trades of the Regulus Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Equity bought 4,398,602 units of RGLS stock worth $2,727,133 on 4 December 2020.
The largest trade Equity's ever made was buying 4,398,602 units of Regulus Therapeutics Inc stock on 4 December 2020 worth over $2,727,133. On average, Equity trades about 1,383,827 units every 144 days since 2019. As of 4 December 2020 Equity still owns at least 6,451,056 units of Regulus Therapeutics Inc stock.
You can see the complete history of Equity Llc stock trades at the bottom of the page.
Over the last 12 years, insiders at Regulus Therapeutics Inc have traded over $78,282,075 worth of Regulus Therapeutics Inc stock and bought 65,288,007 units worth $66,275,578 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Regulus Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $890,488. The most recent stock trade was executed by Kathryn J Collier on 25 July 2024, trading 4,000 units of RGLS stock currently worth $7,280.
regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg
Regulus Therapeutics Inc executives and other stock owners filed with the SEC include: